Pharmaceuticals & Biotech Nigerian Community

Fidson Healthcare Plc delivered a strong top-line performance in H1 2025, recording a 68% YoY increase in revenue from ₦37.3 billion to ₦62.6 billion. Despite facing macroeconomic challenges including rising finance costs and exchange rate volatility, the company grew its profit after tax by nearly 4x, reaching ₦6.02 billion (vs.

MeCure Industries Plc has delivered exceptional growth in Q2 2025, highlighted by a 634% YoY surge in pre-tax profit and 165% revenue growth , driven primarily by booming demand in its acute care and OTC product segments. The company’s sharp revenue and margin expansion have firmly placed it on an upward profitability trajectory.

Neimeth Pharmaceuticals Delivers Strong Turnaround in H1 2025 Despite Financing Cost Pressures Neimeth International Pharmaceuticals Plc posted a robust recovery in its half-year 2025 earnings, underpinned by strong revenue growth and operational efficiency, despite the lingering drag of elevated finance costs. Key Highlights: Revenue Surge : Neimeth reported a 76% year-on-year increase in revenue to ₦2.91 billion in H1 2025, up from ₦1.66 billion in H1 2024.